{"id":7239,"date":"2024-09-17T11:15:00","date_gmt":"2024-09-17T09:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/"},"modified":"2024-09-17T11:15:00","modified_gmt":"2024-09-17T09:15:00","slug":"nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/","title":{"rendered":"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att f\u00f6rsta patienten i tredje och sista dosgruppen i bolagets fas-I-studie med sin dep\u00e5formulering av GLP-1-analogen liraglutid doserats. Studien inleddes i juni 2024 och hittills har tv\u00e5 p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser studerats.<\/strong><\/p>\n<\/div>\n

\n

Prelimin\u00e4ra data fr\u00e5n de tv\u00e5 f\u00f6rsta dosgrupperna visar att bolagets PharmaShell\u00ae-teknologi m\u00f6jligg\u00f6r en kontrollerad och f\u00f6rl\u00e4ngd fris\u00e4ttning av liraglutid med proportionellt \u00f6kad koncentration i plasma med \u00f6kande dos. S\u00e4kerhetsprofilen har varit fortsatt god med endast milda lokala reaktioner vid injektionsst\u00e4llet.<\/p>\n

\u201cVi \u00e4r mycket n\u00f6jda med hur studien har fortl\u00f6pt hittills och ser fram emot att ha kompletta resultat f\u00f6re \u00e5rets slut. De farmakokinetiska resultaten kommer att vara avg\u00f6rande f\u00f6r optimeringen av NEX-22 med m\u00e5let att utveckla en m\u00e5nadsdep\u00e5 att ta vidare i den fortsatta kliniska utvecklingen \u201d s\u00e4ger David Westberg, VD p\u00e5 Nanexa.<\/p>\n

Parallellt p\u00e5g\u00e5r aktiviteter f\u00f6r att ytterligare utveckla PharmaShell\u00ae formuleringen och f\u00f6rbereda n\u00e4sta steg i det kliniska utvecklingsprogrammet f\u00f6r NEX-22.<\/p>\n

I studien ges dep\u00e5formuleringen av NEX-22 subkutant (en injektion under huden). Studien \u00e4r designad att inkludera flera p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser och syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.<\/p>\n

Glukagonliknande peptid-1 (GLP-1) receptoragonister \u00e4r en klass av l\u00e4kemedel f\u00f6r behandling av typ 2-diabetes och fetma. Liraglutid \u00e4r en GLP-1-analog som ing\u00e5r i de idag marknadsf\u00f6rda produkterna Victoza och Saxenda f\u00f6r dagliga injektioner.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att f\u00f6rsta patienten i tredje och sista dosgruppen i bolagets fas-I-studie med sin dep\u00e5formulering av GLP-1-analogen liraglutid doserats. Studien inleddes i juni 2024 och hittills har tv\u00e5 p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser studerats.<\/p>\n","protected":false},"template":"","class_list":["post-7239","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att f\u00f6rsta patienten i tredje och sista dosgruppen i bolagets fas-I-studie med sin dep\u00e5formulering av GLP-1-analogen liraglutid doserats. Studien inleddes i juni 2024 och hittills har tv\u00e5 p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser studerats.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\\\/\",\"name\":\"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-09-17T09:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB","og_description":"Nanexa AB meddelar idag att f\u00f6rsta patienten i tredje och sista dosgruppen i bolagets fas-I-studie med sin dep\u00e5formulering av GLP-1-analogen liraglutid doserats. Studien inleddes i juni 2024 och hittills har tv\u00e5 p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser studerats.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/","name":"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-09-17T09:15:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-paborjar-sista-dosgruppen-i-fas-i-studie-med-nex-22-for-behandling-av-typ-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa p\u00e5b\u00f6rjar sista dosgruppen i fas I-studie med NEX-22 f\u00f6r behandling av typ 2-diabetes"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}